Company intelligence / Profile preview

KFBIO

Yuyao, Zhejiang, Chinakfbiopathology.com ↗

Ownership: Private
Development stage: Commercial

Overview

KFBIO has developed and commercialized a comprehensive suite of digital pathology products including high-throughput slide scanners with CE certification and medical device registration in China. Their AI-powered diagnostic tools are used for screening cancers such as cervical and thyroid cancers. The company claims the largest market share for digital pathology scanners in China (>40%) with over 1500 devices operating worldwide[5]. They have established international partnerships to expand into emerging markets like India[3].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Artificial Intelligence
Industry: Pathology

Partnerships

Intel (co-development of end-to-end digital pathology solutions)Crosscope (distribution/technology partnership for India & emerging markets)

Beyond the preview

Go deeper on KFBIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KFBIO.

Explore the full profile